$131 Million is the total value of Stonepine Capital Management, LLC's 21 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 58.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LGND | Buy | LIGAND PHARMACEUTICALS | $32,431,000 | +5.8% | 326,100 | +1.4% | 24.83% | -22.1% |
| AMYT | Buy | AMRYT PHARMA LTD - SPNR ADRsponsored ads | $20,057,000 | +112.1% | 1,416,483 | +85.1% | 15.36% | +56.1% |
| DMAC | Sell | DIAMEDICA THERAPEUTICS INC | $9,633,000 | +98.2% | 950,000 | -17.1% | 7.38% | +45.8% |
| AYTU | New | AYTU BIOSCIENCE INC | $8,365,000 | – | 1,398,776 | +100.0% | 6.40% | – |
| APEN | Buy | APOLLO ENDOSURGERY INC | $7,909,000 | +228.3% | 2,326,165 | +63.2% | 6.06% | +141.6% |
| CTIC | Sell | CTI BIOPHARMA CORP | $6,614,000 | -18.4% | 2,054,000 | -45.5% | 5.06% | -39.9% |
| ISEE | Sell | IVERIC BIO INC | $5,528,000 | -58.5% | 800,000 | -66.1% | 4.23% | -69.5% |
| XOMA | Sell | XOMA CORP | $5,478,000 | +93.6% | 124,130 | -17.4% | 4.19% | +42.5% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $5,265,000 | -13.2% | 834,449 | -40.9% | 4.03% | -36.1% |
| SCYX | New | SCYNEXIS INC | $5,240,000 | – | 685,000 | +100.0% | 4.01% | – |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $3,501,000 | +29.2% | 808,431 | +23.0% | 2.68% | -4.9% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $3,281,000 | -18.8% | 1,350,000 | -29.9% | 2.51% | -40.3% |
| GMDA | New | GAMIDA CELL LTD | $3,184,000 | – | 379,470 | +100.0% | 2.44% | – |
| CHMA | Buy | CHIASMA INC | $3,138,000 | +108.5% | 721,307 | +106.1% | 2.40% | +53.4% |
| NEOS | Buy | NEOS THERAPEUTICS INC | $3,100,000 | +33.3% | 4,962,657 | +13.2% | 2.37% | -1.9% |
| NVUS | New | NOVUS THERAPEUTICS INC | $2,577,000 | – | 167,333 | +100.0% | 1.97% | – |
| YMTX | New | YUMANITY THERAPEUTICS INC | $1,850,000 | – | 108,847 | +100.0% | 1.42% | – |
| AFMD | Sell | AFFIMED NV | $1,277,000 | +5.4% | 219,340 | -38.7% | 0.98% | -22.4% |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $970,000 | – | 500,000 | +100.0% | 0.74% | – |
| APVO | New | APTEVO THERAPEUTICS INC | $670,000 | – | 18,280 | +100.0% | 0.51% | – |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $557,000 | -70.6% | 188,703 | -68.0% | 0.43% | -78.4% |
| PROG | Exit | PROGENITY INC | $0 | – | -68,062 | -100.0% | -0.64% | – |
| Exit | INTERPACE BIOSCIENCES INC | $0 | – | -284,730 | -100.0% | -0.92% | – | |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -1,205,501 | -100.0% | -3.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.